Theriva Biologics (NYSEAMERICAN:TOVX) Upgraded to “Buy” at Maxim Group

Maxim Group upgraded shares of Theriva Biologics (NYSEAMERICAN:TOVX) from a hold rating to a buy rating in a research report report published on Tuesday,Benzinga reports. The firm currently has $1.00 target price on the stock.

Theriva Biologics Stock Performance

NYSEAMERICAN TOVX opened at $0.20 on Tuesday. Theriva Biologics has a fifty-two week low of $0.16 and a fifty-two week high of $1.50. The stock has a market cap of $6.61 million, a price-to-earnings ratio of -0.01 and a beta of 0.54. The business has a fifty day moving average of $0.19 and a 200-day moving average of $0.26. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings data on Thursday, March 12th. The company reported $1.30 EPS for the quarter.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP acquired a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by institutional investors and hedge funds.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.